clinical trials

Clinical trials, particularly in China's burgeoning biotech sector, are currently facing significant hurdles. The demand for primate experimental models, crucial for preclinical research, has surged, leading to a shortage that could impede biotech growth. This demand is driven by the recovery of fundraising and out-licensing deals in innovative drug development. Adding to these concerns, a recent tragedy involving the death of a child after receiving an experimental gene-editing therapy has brought to light serious failures in risk assessment, transparency, and institutional oversight within these trials. This event has sparked fears of a policy backlash, potentially jeopardizing the rapid expansion of China's biotech industry. The current relevance of these clinical trials is underscored by the critical need for robust ethical frameworks and stringent regulatory oversight to ensure patient safety and maintain public trust, especially as the field of gene editing advances.